In December 2011, our scientists presented multiple posters and presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, CA. We shared data from two programs within our “Alnylam 5×15” product pipeline, including pre-clinical data from ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia,…
View the refractory anemia presentation (680 KB PPT) View the hemophilia poster (1.88 MB PDF) View the beta-thalassemia poster (112 KB PDF) View the erythropoiesis poster (435 KB PDF) Read our press releasePosts Tagged with: Refractory Anemia
December 13, 2011
Alnylam Scientists Present New Data on RNAi Therapeutics at 53rd ASH Annual Meeting
July 24, 2011
“Alnylam 5×15″ Product Strategy
In January 2011, we were very excited to launch our Alnylam 5×15™RNAi therapeutic product strategy. Alnylam 5×15 was established to focus on the development and commercialization of novel RNAi therapeutics addressing genetically defined diseases with major unmet medical need.
Read our press release Listen to our CEO discuss our 5×15 Strategy (4.7MB MP3) Rare Disease Day podcast (7.2MB MP3)